Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Gracell Biotechnologies Inc. (GRCL)

4.99   -0.42 (-7.76%) 06-26 22:50
Open: 5.42 Pre. Close: 5.41
High: 5.4331 Low: 4.85
Volume: 121,481 Market Cap: 337(M)
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.44 - 5.46 5.46 - 5.49
Low: 4.79 - 4.82 4.82 - 4.84
Close: 4.95 - 4.99 4.99 - 5.03

Technical analysis

as of: 2022-06-24 4:40:22 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 6.64     One year: 7.76
Support: Support1: 3.79    Support2: 2.62
Resistance: Resistance1: 5.69    Resistance2: 6.64
Pivot: 3.96
Moving Average: MA(5): 5     MA(20): 3.72
MA(100): 2.94     MA(250): 7.02
MACD: MACD(12,26): 0.5     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 84.4     %D(3): 86.4
RSI: RSI(14): 70.7
52-week: High: 15  Low: 1.67
Average Vol(K): 3-Month: 149 (K)  10-Days: 174 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ GRCL ] has closed below upper band by 18.9%. Bollinger Bands are 164.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Headline News

Mon, 13 Jun 2022
Should You Accumulate Gracell Biotechnologies Inc (GRCL) Stock Monday Morning? - InvestorsObserver

Thu, 09 Jun 2022
Gracell Biotechnologies Inc. (NASDAQ:GRCL) Forecasted to Post FY2023 Earnings of ($0.28) Per Share - MarketBeat

Wed, 01 Jun 2022
Gracell Biotechnologies (NASDAQ:GRCL) Now Covered by Cantor Fitzgerald - MarketBeat

Wed, 01 Jun 2022
Gracell Biotechnologies (GRCL) Stock Price: Why It Increased Over 14% Today - Pulse 2.0

Fri, 27 May 2022
Gracell Biotechnologies (NASDAQ:GRCL) Price Target Cut to $10.00 by Analysts at Piper Sandler - MarketBeat

Mon, 23 May 2022
Is Gracell Biotechnologies Inc (GRCL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 68 (M)
% Held by Insiders 2.049e+007 (%)
% Held by Institutions 7.7 (%)
Shares Short 634 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.7542e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -143
Return on Assets (ttm) 745.3
Return on Equity (ttm) -15.3
Qtrly Rev. Growth 366000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -5.69
Qtrly Earnings Growth -1.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 920.28
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 578610
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.